Lymphocytic Leukemia, Chronic News

Expert Discusses Ongoing Advances in CLL - OncLive



OncLive
 
Expert Discusses Ongoing Advances in CLL 
OncLive
Over the past several years, there have been several key developments in the treatment landscape for patients with chronic lymphocytic leukemia (CLL), particularly with the approvals of novel agents such as ibrutinib (Imbruvica) and venetoclax ...

and more » 


A Personalized Era in Chronic Lymphocytic Leukemia Treatment - Curetoday.com



Curetoday.com
 
A Personalized Era in Chronic Lymphocytic Leukemia Treatment 
Curetoday.com
CLL is a type of blood cancer, most commonly diagnosed in adults, that affects a type of white blood cell, a B lymphocyte, which grows in bone marrow. The disease often progresses slowly, although a faster-growing variation ? SLL ? tends to keep ...

 


Chronic Lymphocytic Leukemia Advisor - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Chronic Lymphocytic Leukemia Advisor 
Cancer Therapy Advisor
NFATC1 activation, which occurs downstream of B cell receptor signaling, prevents apoptosis of chronic lymphocytic leukemia (CLL) cells and may represent a therapeutic target in the relapsed/refractory disease setting, according to a paper published in ...

 


Dr. Wierda Discusses Sequencing New Agents in CLL - OncLive



OncLive
 
Dr. Wierda Discusses Sequencing New Agents in CLL 
OncLive
William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing new agents in chronic lymphocytic leukemia (CLL). With a plethora of novel agents approved in CLL, ...

 


Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation - Oncology Nurse Advisor



Oncology Nurse Advisor
 
Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation 
Oncology Nurse Advisor
The researchers assessed data from a clinical study in which 133 patients with relapsed/refractory B-cell ALL (B-ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) received lymphodepletion chemotherapy followed by CD19 CAR-T ...

 


TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial - GlobeNewswire (press release)



Press Telegraph
 
TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial 
GlobeNewswire (press release)
UNITY-CLL is a global Phase 3 randomized controlled clinical trial in patients with Chronic Lymphocytic Leukemia (CLL) that includes two key objectives: first, was to demonstrate contribution of each agent in the TG-1101 (ublituximab) + TGR-1202 ...
TG stumbles on FDA feedback for cancer combo BioPharma Dive
Why TG Therapeutics Is Tumbling 15% Today Motley Fool
Enrollment complete in TG's late-stage study TG-1101/TG-1202 combo in CLL Seeking Alpha

all 58 news articles » 


FDA Grants Priority Review to Durvalumab for Locally Advanced Unresectable NSCLC - OncLive



OncLive
 
FDA Grants Priority Review to Durvalumab for Locally Advanced Unresectable NSCLC 
OncLive
MEDI4736-NHL-001, exploring the drug as a monotherapy in patients with lymphoma or chronic lymphocytic leukemia, and MEDI4736-DLBCL-001, assessing durvalumab in combination with R-CHOP or R2 CHOP, where also given a partial hold. Patients ...

and more » 


Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic Lymphocytic ... - Business Wire (press release)



OncLive
 
Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic Lymphocytic ... 
Business Wire (press release)
?Chronic lymphocytic leukemia is considered incurable and becomes harder to treat with each relapse,? said Sandra Horning, M.D., chief medical officer and head of Global Product Development. ?This is the first study to show that Venclexta plus Rituxan ...
Venetoclax Combination Improves PFS in Phase III CLL Trial OncLive
AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA?/VENCLYXTO? (Venetoclax ... PR Newswire (press release)
Venclexta/Rituxan Combo Slows CLL Progression P&T Community
Endpoints News  -Seeking Alpha 
all 6 news articles » 


ETF Preview: ETFs, Futures Higher Following 3-Month Rise in Empire State Manufacturing Index - Nasdaq



ETF Preview: ETFs, Futures Higher Following 3-Month Rise in Empire State Manufacturing Index 
Nasdaq
TG Therapeutics (TGTX) shares fell 10% after the company gave an update on its meeting regarding the use of results from a phase 3 trial in support of a biologics license application for TG-1101 for chronic lymphocytic leukemia. The company said the ...

and more » 


Examining the Safety of CLL Medication - Curetoday.com



Examining the Safety of CLL Medication 
Curetoday.com
OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include ...